- Home
- KTTA vs MBIO Comparison
KTTA vs MBIO Comparison
Compare KTTA & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KTTA
- MBIO
- Stock Information
- Founded
- KTTA 2020
- MBIO 2015
- Country
- KTTA United States
- MBIO United States
- Employees
- KTTA N/A
- MBIO N/A
- Industry
- KTTA Biotechnology: Pharmaceutical Preparations
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- KTTA Health Care
- MBIO Health Care
- Exchange
- KTTA Nasdaq
- MBIO Nasdaq
- Market Cap
- KTTA 5.7M
- MBIO 4.7M
- IPO Year
- KTTA 2021
- MBIO N/A
- Fundamental
- Price
- KTTA $0.81
- MBIO $1.45
- Analyst Decision
- KTTA
- MBIO
- Analyst Count
- KTTA 0
- MBIO 0
- Target Price
- KTTA N/A
- MBIO N/A
- AVG Volume (30 Days)
- KTTA 99.4K
- MBIO 128.9K
- Earning Date
- KTTA 11-14-2025
- MBIO 11-12-2025
- Dividend Yield
- KTTA N/A
- MBIO N/A
- EPS Growth
- KTTA N/A
- MBIO N/A
- EPS
- KTTA N/A
- MBIO N/A
- Revenue
- KTTA N/A
- MBIO N/A
- Revenue This Year
- KTTA N/A
- MBIO N/A
- Revenue Next Year
- KTTA N/A
- MBIO N/A
- P/E Ratio
- KTTA N/A
- MBIO N/A
- Revenue Growth
- KTTA N/A
- MBIO N/A
- 52 Week Low
- KTTA $0.65
- MBIO $0.89
- 52 Week High
- KTTA $4.35
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- KTTA 58.89
- MBIO 40.72
- Support Level
- KTTA $0.71
- MBIO $1.43
- Resistance Level
- KTTA $0.84
- MBIO $1.69
- Average True Range (ATR)
- KTTA 0.05
- MBIO 0.08
- MACD
- KTTA 0.01
- MBIO -0.01
- Stochastic Oscillator
- KTTA 82.47
- MBIO 17.24
About KTTA Pasithea Therapeutics Corp.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.